

Carl R Alving

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3311743/publications.pdf>

Version: 2024-02-01

43
papers

1,986
citations

257450

24
h-index

265206

42
g-index

44
all docs

44
docs citations

44
times ranked

1866
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcutaneous immunization: A human vaccine delivery strategy using a patch. <i>Nature Medicine</i> , 2000, 6, 1403-1406.	30.7	327
2	Skin immunization made possible by cholera toxin. <i>Nature</i> , 1998, 391, 851-852.	27.8	250
3	Design and selection of vaccine adjuvants: animal models and human trials. <i>Vaccine</i> , 2002, 20, S56-S64.	3.8	108
4	Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. <i>Expert Review of Vaccines</i> , 2012, 11, 733-744.	4.4	107
5	Liposomal adjuvants for human vaccines. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 807-816.	5.0	85
6	The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil [®]). <i>Journal of Liposome Research</i> , 2000, 10, 467-481.	3.3	75
7	Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs. <i>Vaccine</i> , 2013, 31, 2804-2810.	3.8	69
8	Efficacy, but Not Antibody Titer or Affinity, of a Heroin Hapten Conjugate Vaccine Correlates with Increasing Hapten Densities on Tetanus Toxoid, but Not on CRM ₁₉₇ Carriers. <i>Bioconjugate Chemistry</i> , 2015, 26, 1041-1053.	3.6	61
9	Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. <i>Vaccine</i> , 2015, 33, 5578-5587.	3.8	60
10	Army Liposome Formulation (ALF) family of vaccine adjuvants. <i>Expert Review of Vaccines</i> , 2020, 19, 279-292.	4.4	59
11	Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMPO13. <i>Vaccine</i> , 2017, 35, 3865-3874.	3.8	58
12	Natural antibodies against phospholipids and liposomes in humans. <i>Biochemical Society Transactions</i> , 1984, 12, 342-343.	3.4	50
13	Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. <i>Vaccine</i> , 2017, 35, 5448-5454.	3.8	49
14	Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amoebocyte lysate. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 775-780.	2.6	48
15	Advances in vaccine delivery: transcutaneous immunisation. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 797-805.	4.1	46
16	Principles of transcutaneous immunization using cholera toxin as an adjuvant. <i>Vaccine</i> , 1999, 17, S37-S43.	3.8	43
17	LIGHT-INDUCED LEAKAGE OF SPIN LABEL MARKER FROM LIPOSOMES IN THE PRESENCE OF PHOTOTOXIC PHENOTHIAZINES. <i>Photochemistry and Photobiology</i> , 1976, 24, 41-48.	2.5	39
18	Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. <i>Journal of Controlled Release</i> , 2018, 275, 12-19.	9.9	39

#	ARTICLE	IF	CITATIONS
19	Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). <i>Vaccine</i> , 2019, 37, 3793-3803.	3.8	39
20	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , 2020, 16, e1008764.	4.7	37
21	Naturally occurring autoantibodies to cholesterol in humans. <i>Biochemical Society Transactions</i> , 1989, 17, 637-639.	3.4	35
22	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. <i>Npj Vaccines</i> , 2017, 2, 13.	6.0	34
23	Oil-in-Water Liposomal Emulsions for Vaccine Delivery. <i>Methods in Enzymology</i> , 2003, 373, 34-50.	1.0	33
24	Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. <i>Annals of Tropical Medicine and Parasitology</i> , 1984, 78, 279-286.	1.6	29
25	Complement-Dependent Phagocytosis of Liposomes: Suppression by "Stealth" Lipids. <i>Journal of Liposome Research</i> , 1992, 2, 383-395.	3.3	25
26	Studies on the Topography of the Catalytic Site of Acetylcholinesterase Using Polyclonal and Monoclonal Antibodies. <i>Journal of Neurochemistry</i> , 1990, 55, 756-763.	3.9	24
27	Complement Activation by Liposome-Encapsulated Hemoglobin In Vitro: The Role of Endotoxin Contamination. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 1995, 23, 355-363.	0.9	19
28	Complement-Mediated Acute Effects of Liposome-Encapsulated Hemoglobin. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 1999, 27, 23-41.	0.9	18
29	Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria. <i>Vaccines</i> , 2021, 9, 272.	4.4	16
30	Immune Reactivities of Antibodies against Glycolipids. <i>ACS Symposium Series</i> , 1980, , 461-473.	0.5	14
31	Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. <i>Npj Vaccines</i> , 2021, 6, 148.	6.0	14
32	Life-Long Administration of Liposomes and Lipid A in Mice: Effects on Longevity, Antibodies to Liposomes, and Terminal Histopathological Patterns. <i>Journal of Liposome Research</i> , 1988, 1, 93-110.	3.3	13
33	Polymeric biodegradable lipospheres as vaccine delivery systems. <i>Polymers for Advanced Technologies</i> , 1992, 3, 351-357.	3.2	13
34	Liposome Formulations as Adjuvants for Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2021, 433, 1-28.	1.1	9
35	Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. <i>Journal of Liposome Research</i> , 2019, 29, 247-250.	3.3	8
36	Liposomes as carriers for a human malaria sporozoite vaccine. <i>Biochemical Society Transactions</i> , 1988, 16, 921-922.	3.4	6

#	ARTICLE	IF	CITATIONS
37	Prospects for an Anticholesterol Vaccine. <i>BioDrugs</i> , 1995, 3, 409-414.	0.7	6
38	Toxic effects of antileishmanial reverse-phase evaporation liposomes containing dicetyl phosphate in monkeys. <i>Drug Delivery</i> , 1995, 2, 181-189.	5.7	5
39	Emulsification of Liposomes with Incomplete Freund's Adjuvant: Stability of the Liposomes and the Emulsion. <i>Journal of Liposome Research</i> , 1998, 8, 183-194.	3.3	5
40	Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a <i>Leishmania major</i> challenge. <i>Vaccine</i> , 2019, 37, 516-523.	3.8	4
41	Walter Reed Army Institute of Research (WRAIR): Fifty Years of Achievements That Impact Science and Society. <i>Military Medicine</i> , 2021, 186, 72-77.	0.8	4
42	Army liposome formulation containing QS-21 render human monocyte-derived macrophages less permissive to HIV-1 infection by upregulating APOBEC3A. <i>Scientific Reports</i> , 2022, 12, 7570.	3.3	3
43	Commentary: Some Thoughts on an International Liposome Society. <i>Journal of Liposome Research</i> , 1999, 9, ix-xii.	3.3	0